Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Lee HJ, et al. Among authors: zhang l. Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13. Oncologist. 2017. PMID: 28408615 Free PMC article. Clinical Trial.
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Jain P, et al. Among authors: zhang l. Br J Haematol. 2018 Aug;182(3):404-411. doi: 10.1111/bjh.15411. Epub 2018 May 22. Br J Haematol. 2018. PMID: 29785709 Free article. Clinical Trial.
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Jain P, et al. Among authors: zhang l, zhang s. Br J Haematol. 2018 Nov;183(4):578-587. doi: 10.1111/bjh.15567. Epub 2018 Sep 2. Br J Haematol. 2018. PMID: 30175400 Free article.
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Wang M, et al. Among authors: zhang l. Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. doi: 10.1586/14737140.6.7.983. Expert Rev Anticancer Ther. 2006. PMID: 16831071 Review.
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Wang M, et al. Among authors: zhang l. Lancet Oncol. 2012 Jul;13(7):716-23. doi: 10.1016/S1470-2045(12)70200-0. Epub 2012 Jun 6. Lancet Oncol. 2012. PMID: 22677155 Clinical Trial.
NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. Li Y, et al. Among authors: zhang l. Blood Cancer J. 2017 Nov 23;7(12):632. doi: 10.1038/s41408-017-0005-z. Blood Cancer J. 2017. PMID: 29167454 Free PMC article. No abstract available.
125,294 results
You have reached the last available page of results. Please see the User Guide for more information.